Associated Papers
Clinically actionable cancer somatic variants (CACSV): a tumor interpreted dataset for analytical workflows.
Sobahy TM et al.
Bmc Medical Genomics, 2022
35468810 (PubMed )
Supplement: 12920_2022_1235_MOESM2_ESM.xlsx › Sheet1
Sequence-structure functional implications and molecular simulation of high deleterious nonsynonymous substitutions in IDH1 revealed the mechanism of drug resistance in glioma.
Suleman M et al.
Frontiers in Pharmacology, 2022
Deep Genomic Sequencing of Bladder Urothelial Carcinoma in Southern Chinese Patients: A Single-Center Study.
Li DY et al.
Frontiers in Oncology, 2021
34055593 (PubMed )
Supplement: Table_2.xlsx › CNVs_and_SNVs
Feasibility of next-generation sequencing in clinical practice: results of a pilot study in the Department of Precision Medicine at the University of Campania 'Luigi Vanvitelli'.
De Falco V et al.
Esmo Open, 2020
32234730 (PubMed )
Supplement: esmoopen-2020-000675supp003.pdf
Epigenetic Enzyme Mutations: Role in Tumorigenesis and Molecular Inhibitors.
Han M et al.
Frontiers in Oncology, 2019
Genomic Profile and BRCA-1 Promoter Methylation Status in BRCA Mutated Ovarian Cancer: New Insights in Predictive Biomarkers of Olaparib Response.
Franzese E et al.
Frontiers in Oncology, 2019
Role of isocitrate dehydrogenase 1/2 (IDH 1/2) gene mutations in human tumors.
Liu X et al.
Histology and Histopathology, 2015
Mixed T/myeloid phenotype acute leukemia with rare variants of IDH1 and CEBPA.
Ma Q et al.
Leukemia & Lymphoma, 2013
IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma.
Zhang C et al.
Neuro-oncology, 2013
Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production.
Ward PS et al.
Oncogene, 2012
Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease.
Paugh BS et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2010
TP53, ATRX alterations, and low tumor mutation load feature IDH-wildtype giant cell glioblastoma despite exceptional ultra-mutated tumors.
Cantero D et al.
Neuro-oncology Advances, 0
Select a paper to view details